Quantcast

Latest Prostate cancer Stories

2014-04-15 12:30:48

Major Production Increase Being Undertaken To Meet Growing Demand BETHESDA, Md., April 15, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of the first $15 million funding by a single institutional investor of the registered direct placement of up to $32 million which was announced by the Company last week. These first 2.27 million...

2014-04-15 08:29:16

Trial Will Evaluate Investigational Compound's Efficacy and Safety as an Addition to Standard Chemotherapy in Previously-Untreated Patients NORTH CHICAGO, Ill., April 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). The trial...

2014-04-15 08:28:19

Phase III Trial Now Recruiting Patients SANTA ROSA, Calif., April 15, 2014 /PRNewswire/ -- A phase III clinical trial conducted at the Meir Medical Center in Kfar-Saba, Israel is now recruiting participants to study the effects of dietary supplement PectaSol-C® modified citrus pectin (MCP) in controlling prostate specific antigen (PSA) levels in prostate cancer patients. "MCP has shown activity against prostate and other cancers in a number of previous studies, and toxicology...

2014-04-14 23:08:01

A recent published review of the link between Actos and bladder cancer suggests that a federal jury’s judgment against the drug’s manufacturer is justified. Raleigh, NC (PRWEB) April 14, 2014 Earlier this week, a jury awarded $9 billion in punitive damages to a man who says he got bladder cancer from taking the diabetes drug Actos. (Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al, No. 6:12-cv-00064) According to cancer information site Cancer Monthly,...

2014-04-13 23:01:22

Days after a federal jury announced a $9 billion dollar judgment against the drug’s manufacturers, Cancer Monthly is encouraging bladder cancer patients to know their rights. Raleigh, NC (PRWEB) April 13, 2014 The Japanese manufacturer of the diabetes drug Actos and its partner firm, Eli Lilly & Co., have been ordered to pay $9 billion to Terrence Allen, who was diagnosed with bladder cancer after taking Actos. (Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc.,...

2014-04-12 23:01:34

A Louisiana jury’s decision to award $9 billion in damages to a man who says his bladder cancer was caused by the drug Actos could pave a new legal path for other bladder cancer patients. Raleigh, NC (PRWEB) April 12, 2014 Bladder cancer patients who took the drug Actos to control diabetes may now be able to establish a legal nexus or connection between the drug and the disease, thanks to a high-profile legal decision made this week.* If you are a bladder cancer patient who took Actos,...

2014-04-12 23:00:02

ResearchMoz.us include new market research report "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" to its huge collection of research reports.Full Report With TOC at http://www.researchmoz.us/metastatic-hormone-refractory-castration-resistant-androgen-independent-prostate-cancer-pipeline-review-h1-2014-report.html. Albany, NY (PRWEB) April 13, 2014 Researchmoz presents this most up-to-date research on...

2014-04-11 11:57:29

Most breast cancers are treated by blocking their addictions, for example depriving estrogen-fueled tumors of estrogen. But what about breast cancers without these hormonal addictions? In so-called "triple negative" tumors the cancer's addiction remains a mystery, making this subtype difficult to treat. However, a University of Colorado Cancer Center study presented today at the American Association for Cancer Research (AACR) Annual Meeting 2014 showcased a new drug active against...

2014-04-11 08:24:36

SAN DIEGO, April 11, 2014 /PRNewswire/ -- GenomeDx Biosciences announced today that two study abstracts for the company's genomic tests for prostate and bladder cancers have been selected as "Best Posters in a Poster Session" by conference organizers at the 29(th) Annual European Association of Urology Congress. The first poster presentation demonstrates the clinical validation of the Decipher® prostate cancer classifier for predicting treatment failure in men treated with...

2014-04-10 08:28:33

DUBLIN, April 10, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/qxfqmk/drug_delivery_in) has announced the addition of a new report "Drug Delivery in Cancer - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/qxfqmk/drug_delivery_in ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Drug delivery remains a challenge in management of cancer. Approximately 12.5...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related